[go: up one dir, main page]

WO2014184309A1 - Composés [1,2,4]triazole et imidazole substitués - Google Patents

Composés [1,2,4]triazole et imidazole substitués Download PDF

Info

Publication number
WO2014184309A1
WO2014184309A1 PCT/EP2014/060000 EP2014060000W WO2014184309A1 WO 2014184309 A1 WO2014184309 A1 WO 2014184309A1 EP 2014060000 W EP2014060000 W EP 2014060000W WO 2014184309 A1 WO2014184309 A1 WO 2014184309A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
och3
chf2
compounds
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/060000
Other languages
English (en)
Inventor
Wassilios Grammenos
Ian Robert CRAIG
Nadege Boudet
Bernd Müller
Erica May Wilson LAUTERWASSER
Jan Klaas Lohmann
Egon Haden
Ana Escribano Cuesta
Thomas Grote
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of WO2014184309A1 publication Critical patent/WO2014184309A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
    • A01N43/647—Triazoles; Hydrogenated triazoles
    • A01N43/653—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • J. Agric. Food Chem. 2009, 57, 4854-4860 describes certain bistriazoles and triazole- imidazoles and their use as fungicide.
  • EP 0 044 605 relates to fungicidal bisazolyls, in particular bis triazolyl compounds.
  • CN 1923819 relates to bistriazoles.
  • the present invention relates to com ounds of the formula I
  • X is CH or N
  • Y is CH or N
  • R 2 is Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Cs-Cs-cycloalkyl, C3-C8-cycloalkyl-Ci-C6-alkyl, phenyl, phenyl-Ci-C4-alkyl, phenyl-C2-C4-alkenyl or phenyl-C2-C4-alkyl;
  • aliphatic moieties of R 2 may carry one, two, three or up to the maximum possible number of identical or different groups R 2a which independently of one another are selected from:
  • R 2a halogen, OH, CN, nitro, Ci-C4-alkoxy, Cs-Cs-cycloalkyl, Cs-Cs-halocycloalkyl and C1-C4- halogenalkoxy;
  • cycloalkyi and/or phenyl moieties of R 2 may carry one, two, three, four, five or up to the maximum number of identical or different groups R 2b which independently of one another are selected from:
  • R 2b halogen, OH, CN, nitro, Ci-C4-alkyl, Ci-C4-alkoxy, Ci-C4-halogenalkyl, Cs-Cs-cycloalkyl, C3-Cs-halocycloalkyl and Ci-C4-halogenalkoxy; n is 0, 1 , 2, 3 or 4;
  • R 3 is independently selected from halogen, CN, NO2, OH, SH, Ci-C6-alkyl, Ci-C6-alkoxy, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyloxy, NH 2 , NH(Ci-C 4 -alkyl), N(Ci-C 4 -alkyl) 2 , NH(C 3 -C 6 -cycloalkyl), N(C 3 -C 6 -cycloalkyl) 2 , S(0) P (Ci-C 4 -alkyl),
  • R 3a is independently selected from halogen, CN, N0 2 , OH, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C 3 -C 8 - cycloalkyl, C 3 -C8-halocycloalkyl, Ci-C 4 -alkoxy and Ci-C 4 -haloalkoxy;
  • n 0, 1 , 2, 3, 4 or 5;
  • R 4 is independently selected from halogen, CN, N0 2 , OH, SH, Ci-C6-alkyl, Ci-C6-alkoxy, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkyloxy, NH 2 , NH(Ci-C 4 -alkyl), N(Ci-C 4 -alkyl) 2 , NH(C 3 -C 6 -cycloalkyl), N(C 3 -C 6 -cycloalkyl) 2 , S(0) P (Ci-C 4 -alkyl),
  • R 4a is independently selected from halogen, CN, N0 2 , OH, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C 3 -C 8 - cycloalkyl, C 3 -C 8 -halocycloalkyl, Ci-C 4 -alkoxy and Ci-C 4 -haloalkoxy; and wherein
  • p 0, 1 or 2;
  • Compounds I can be obtained from compounds II by reacting the alcohol compound of formula II with R 2 -LG, wherein LG represents a nucleophilically replaceable leaving group, such as halogen, alkylsulfonyl, alkylsulfonyloxy and arylsulfonyloxy, preferably chloro, bromo or iodo, particularly preferably bromo, preferably in the presence of a base.
  • LG represents a nucleophilically replaceable leaving group, such as halogen, alkylsulfonyl, alkylsulfonyloxy and arylsulfonyloxy, preferably chloro, bromo or iodo, particularly preferably bromo, preferably in the presence of a base.
  • X, Y, R 2 , R 3 , R 4 , n and m are as defined herein.
  • X is N and Y is N, corresponding to compounds 11.
  • X is CH and Y is CH, correspond- ing to com ounds II.
  • Table 1f Compounds of the formula II.C in which the meaning for the combination of (R 3 ) n and (R 4 )m for each individual compound corresponds in each case to one line of Table A (com- pounds II.C.A1 to II.C.A2496).
  • inventive compounds cannot be directly obtained by the routes described above, they may be prepared by derivatization of other inventive compounds.
  • the N-oxides may be prepared from the inventive compounds according to conventional oxidation methods, e. g. by treating compounds I with an organic peracid such as metachloroper- benzoic acid (cf. WO 03/64572 or J. Med. Chem. 38(1 1 ), 1892-903, 1995); or with inorganic oxidizing agents such as hydrogen peroxide (cf. J. Heterocyc. Chem. 18(7), 1305-8, 1981 ) or oxone (cf. J. Am. Chem. Soc. 123(25), 5962-5973, 2001 ).
  • the oxidation may lead to pure mono-N-oxides or to a mixture of different N-oxides, which can be separated by conventional methods such as chromatography.
  • C n -C m indicates the number of carbon atoms possible in each case in the substituent or substituent moiety in question.
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • Ci-C6-alkyl refers to a straight-chained or branched saturated hydrocarbon group having 1 to 6 carbon atoms, e.g. methyl, ethyl, propyl, 1 -methylethyl, butyl, 1 -methylpropyl, 2- methylpropyl, 1 ,1 -dimethylethyl, pentyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl,
  • C2-C4-alkyl refers to a straight-chained or branched alkyl group having 2 to 4 carbon atoms, such as ethyl, propyl (n-propyl), 1 -methylethyl (iso-propoyl), butyl, 1 -methylpropyl (sec. -butyl), 2-methylpropyl (iso-butyl), 1 ,1 -dimethylethyl (tert. -butyl).
  • Ci-C6-haloalkyl refers to an alkyl group having 1 or 6 carbon atoms as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above.
  • Examples are "Ci-C2-haloalkyl” groups such as chloromethyl, bro- momethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloro- fluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1 -chloroethyl, 1 -bromoethyl, 1 - fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-
  • C2-C6-alkenyl refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and a double bond in a n position.
  • Examples are “C2-C4-alkenyl” groups, such as ethenyl, 1 -propenyl, 2-propenyl (allyl), 1 -methylethenyl, 1 -butenyl, 2-butenyl,
  • C2-C6-alkynyl refers to a straight-chain or branched unsaturated hydrocarbon radical having 2 to 6 carbon atoms and containing at least one triple bond.
  • Examples are "C2-C4- alkynyl” groups, such as ethynyl, prop-1 -ynyl, prop-2-ynyl (propargyl), but-1 -ynyl, but-2-ynyl, but-3-ynyl, 1 -methyl-prop-2-ynyl.
  • Cs-Cs-cycloalkyl refers to monocyclic saturated hydrocarbon radicals having 3 to 8 carbon ring members, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • C3-C8-cycloalkyl-Ci-C4-alkyl refers to alkyl having 1 to 4 carbon atoms (as defined above), wherein one hydrogen atom of the alkyl radical is replaced by a cycloalkyl radical having 3 to 8 carbon atoms (as defined above).
  • Ci-C6-alkoxy refers to a straight-chain or branched alkyl group having 1 to 6 carbon atoms which is bonded via an oxygen, at any position in the alkyl group.
  • Examples are “C1-C4- alkoxy” groups, such as methoxy, ethoxy, n-propoxy, 1 -methylethoxy, butoxy, 1 - methyhpropoxy, 2-methylpropoxy or 1 ,1 -dimethylethoxy.
  • Ci-C6-haloalkoxy refers to a Ci-C6-alkoxy radical as defined above, wherein some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above.
  • Examples are "Ci-C4-haloalkoxy” groups, such as OCH2F, OCH F2, OCF3, OCH2CI, OCHCI2, OCCI3, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoro- ethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-tri- chloro-"ethoxy, OC2F5, 2-fluoro
  • Agriculturally acceptable salts of the inventive compounds encompass especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, have no adverse effect on the fungicidal action of said compounds.
  • Suitable cations are thus in particular the ions of the alkali metals, preferably sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, of the transition metals, preferably manganese, copper, zinc and iron, and also the ammonium ion which, if desired, may carry one to four Ci-C4-alkyl substituents and/or one phenyl or benzyl substituent, preferably diisopropylammoni- um, tetramethylammonium, tetrabutylammonium, trimethylbenzylammonium, furthermore phos- phonium ions, sulfonium ions, preferably tri(Ci-C4-alkyl)sulfonium, and sul
  • Anions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of Ci-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting such inventive compound with an acid of the corresponding anion, prefera- bly of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.
  • inventive compounds can be present in atropisomers arising from restricted rotation about a single bond of asymmetric groups. They also form part of the subject matter of the present invention.
  • the compounds of formula I and II, respectively, and their N-oxides may have one or more centers of chirality, in which case they are present as pure en- antiomers or pure diastereomers or as enantiomer or diastereomer mixtures. Both, the pure enantiomers or diastereomers and their mixtures are subject matter of the present invention.
  • the embodiments of the compounds I also apply to the intermediates, in particular to compounds II.
  • X according to the invention is N or CH. According to one embodiment X is N. According to a further embodiment X is CH.
  • Y according to the invention is N or CH. According to one embodiment Y is N. According to a further embodiment Y is CH.
  • X and Y are N.
  • X is N and Y is CH.
  • X and Y are CH.
  • R 2 is Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Cs-Cs-cycloalkyl, C3- C8-cycloalkyl-Ci-C6-alkyl, phenyl, phenyl-Ci-C4-alkyl, phenyl-C2-C4-alkenyl or phenyl-C2-C4- alkynyl, wherein the aliphatic moieties of R 2 are not further substituted or carry one, two, three or up to the maximum possible number of identical or different groups R 2a which independently of one another are selected from halogen, OH, CN, nitro, Ci-C4-alkoxy, Cs-Cs-cycloalkyl, C3-C8- halocycloalkyl and Ci-C4-halogenalkoxy; and wherein the cycloalkyl and/or phenyl moieties of R 2 are
  • R 2 is selected from Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, wherein the R 2 are in each case unsubstituted or are substituted by R 2a as defined and preferably defined herein, in particular wherein each R 2a is independently selected from halogen, OH, CN, Ci-C4-alkoxy and Ci-C4-halogenalkoxy, more specifically selected from OH, CN, Ci-C4-alkoxy and Ci-C4-halogenalkoxy. Specific embodiments thereof can be found in the below Table P2.
  • R 2 is selected from Ci-C6-alkyl, C2-C6-alkenyl and C2- C6-alkynyl, wherein the R 2 are in each case unsubstituted or are substituted by R 2a as defined and preferably defined herein.
  • the substituents may also have the preferred meanings for the respective substituent as defined herein. Specific embodiments thereof can be found in the below Table P2.
  • R 2 is Ci-C6-alkyl, in particular Ci-C4-alkyl, such as CH 3 , C 2 H 5 , CH(CH 3 ) 2 , CH2CH2CH3, CH2CH2CH2CH3, CH 2 CH(CH 3 ) 2 .
  • a further embodiment relates to compounds, wherein R 2 is Ci-C6-alkyl, in particular Ci-C4-alkyl, that is substituted by one, two or three or up to the maximum possible number of identical or different groups R 2a , as defined and preferably defined herein.
  • R 2 is C1-C6- haloalkyl, in particular Ci-C4-haloalkyl, more particularly Ci-C2-haloalkyl.
  • R 2 is Ci-C4-alkoxy-Ci-C6-alkyl, in particular Ci-C4-alkoxy-Ci-C4- alkyl, such as CH2OCH3 or CH2CH2OCH3.
  • R 2 is hydroxy-Ci-C6-alkyl, in particular hydroxyl-Ci-C4-alkyl, such as CH2CH2OH.
  • R 2 is cyano-Ci-C6-alkyl, in particular C1-C4- cyano-Ci-C4-alkyl, such as CH2CN or CH2CH2CN. Further specific embodiments thereof can be found in the below Table P2.
  • R 2 is C3-C8-cycloalkyl-Ci-C6-alkyl, in particular C3-C6- cycloalkyl-Ci-C4-alkyl.
  • a further embodiment relates to compounds, wherein R 2 is C3-C8- cycloalkyl-Ci-C6-alkyl, in particular C3-C6-cycloalkyl-Ci-C4-alkyl, more particularly C3-C6- cycloalkyl-Ci-C2-alkyl, that is substituted by one, two or three or up to the maximum possible number of identical or different groups R 2a in the alkyl moiety and/or substituted by one, two, three four or five or up to the maximum possible number of identical or different groups R 2b in the cycloalkyl moiety.
  • R 2a and R 2b are in each case as defined and preferably defined herein. Specific embodiments thereof can be found in the below Table P2.
  • a further embodiment relates to compounds, wherein R 2 is C2-C6-alkenyl, in particular C2-C4-alkenyl, that is substituted by one, two or three or up to the maximum possible number of identical or different groups R 2a as defined and pref- erably defined herein.
  • R 2 is C3-C8-cycloalkyl-C2-C6-alkenyl or C3-C8-halocycloalkyl-C2-C6- alkenyl, in particular C3-C6-cycloalkyl-C2-C4-alkenyl or C3-C6-halocycloalkyl-C2-C4-alkenyl. Further specific embodiments thereof can be found in the below Table P2.
  • R 2 is C2-C6-alkynyl, in particular C2-C4-alkynyl, such as CH2C ⁇ CH or CH2C ⁇ CCH3.
  • a further embodiment relates to compounds, wherein R 2 is C2-C6- alkynyl, in particular C2-C4-alkynyl, that is substituted by one, two or three or up to the maximum possible number of identical or different groups R 2a , as defined and preferably defined herein.
  • R 2 is C2-C6-haloalkynyl, in particular C2-C4- haloalkynyl.
  • R 2 is C3-C8-cycloalkyl-C2-C6- alkynyl or C3-C8-halocycloalkyl-C2-C6-alkynyl, in particular C3-C6-cycloalkyl-C2-C4-alkynyl or C3- C6-halocycloalkyl-C2-C4-alkynyl. Specific embodiments thereof can be found in the below Table P2.
  • R 2 is phenyl-Ci-C4-alkyl, in particular phenyl-Ci-C2-alkyl, such as benzyl, wherein the alkyl moiety in each case is unsubstituted or carries one, two or three R 2a as defined and preferably defined herein, in particular selected from halogen, in par- ticular F and CI, Ci-C4-alkoxy, in particular OCH3, and CN, and wherein the phenyl in each case is unsubstituted or carries one, two or three R 2b as as defined and preferably defined herein, in particular selected from halogen, in particular CI and F, Ci-C4-alkoxy, in particular OCH3, C1-C4- alkyl, in particular CH3 or C2H5, and CN. Specific embodiments thereof can be found in the below Table P2.
  • R 2 is phenyl-C2-C4-alkenyl, in particular phenyl-C2-C3- alkenyl, such as phenylethenyl, wherein the alkenyl moiety in each case is unsubstituted or carries one, two or three R 2a as defined and preferably defined herein, in particular selected from halogen, in particular F and CI, Ci-C4-alkoxy, in particular OCH3, and CN, and wherein the phenyl in each case is unsubstituted or carries one, two or three R 2b as defined and preferably de- fined herein, in particular selected from halogen, in particular CI and F, Ci-C4-alkoxy, in particular OCH3, Ci-C4-alkyl, in particular CH3 or C2H5, and CN.
  • R 2a as defined and preferably defined herein, in particular selected from halogen, in particular F and CI, Ci-C4-alkoxy, in particular OCH3, Ci-
  • R 2 is phenyl-C2-C4-alkynyl, in particular phenyl-C2-C3- alkynyl, such as phenylethinyl, wherein the alkynyl moiety in each case is unsubstituted or carries one, two or three R 2a , as defined and preferably defined herein, in particular selected from halogen, in particular F and CI, Ci-C4-alkoxy, in particular OCH3, and CN, and wherein the phenyl in each case is unsubstituted or carries one, two or three R 2b as defined and preferably defined herein, in particular selected from halogen, in particular CI and F, Ci-C4-alkoxy, in particular OCH3, Ci-C4-alkyl, in particular CH3 or C2H5, and CN.
  • R 2a as defined and preferably defined herein, in particular selected from halogen, in particular F and CI, Ci-C4-alkoxy, in particular OCH3,
  • R 2 is Cs-Cs-cycloalkyl, in particular C3-C6-cycloalkyl, such as C3H5 (cyclopropyl), C4H7 (cyclobutyl), cyclopentyl or cyclohexyl.
  • a further embodiment relates to compounds, wherein R 2 is Cs-Cs-cycloalkyl, in particular C3-C6-cycloalkyl, such as C3H5 (cyclopropyl) or C4H7 (cyclobutyl), that is substituted by one, two, three four or five or up to the maximum possible number of identical or different groups R 2b as defined and preferably defined herein.
  • R 2 is Cs-Cs-halocycloalkyl, in particular C3- C6-halocycloalkyl, such as halocyclopropyl, in particular 1-F-cyclopropyl or 1-CI-cyclopropyl.
  • R 2 is C3-Cs-cycloalkyl-C3-Cs-cycloalkyl, in particular C3-C6-cycloalkyl-C3-C6-cycloalkyl, wherein each of said cycloalkyl-cycloalkyl moieties is unsubstituted or carries one, two or three R 2b as defined and preferably defined herein.
  • R 2 is phenyl, wherein the phenyl is unsubstituted or carries one, two, three, four or five independently selected R 2b as defined and preferably defined herein, in particular selected from halogen, in particular CI and F, Ci-C4-alkoxy, in particular OCHs, Ci-C 4 -alkyl, in particular CH 3 or C 2 H 5 , and CN.
  • R 2 Particularly preferred embodiments of R 2 according to the invention are in Table P2 below, wherein each line of lines P2-1 to P2-87 corresponds to one particular embodiment of the invention, wherein P2-1 to P2-87 are also in any combination a preferred embodiment of the present invention.
  • R 2 More specific embodiments of R 2 according to the invention are in Table B below, wherein each line of lines B-1 to B-13 corresponds to one particular embodiment of the invention, wherein B-1 to B-13 are also in any combination preferred embodiments of the present invention.
  • n 0, 1 , 2, 3 or 4.
  • n 0.
  • n 1
  • n is 2 or 3. According to one specific embodiment thereof, n is 2, according to a further specific embodiment, n is 3.
  • one R 3 is attached to the 2-position in relation to the position of the attachment of the tertiary ether group;(R 31 ).
  • n is 1
  • n is 2.
  • one R 3 is attached to the 3-position in relation to the position of the attachment of the tertiary ether group (R 32 ).
  • n is 1 , according to a further specific embodiment, n is 2.
  • n is 1 , 2 or 3 and one R 3 is in 2-position in relation to the position of the attachment of the tertiary ether group. According to a further embodiment of the invention, two R 3 are attached in 2,3-position in relation to the position of the attachment of the tertiary ether group. According to one specific embodiment thereof, n is 2, according to a further specific embodiment, n is 3.
  • n 2
  • n 3
  • n 2
  • n 3
  • R 3 (or R 31 , R 32 , R 33 , R 34 , respectively) that is present in the inventive compounds
  • the following embodiments and preferences apply independently of the meaning of any other R 3 (or R 31 , R 32 , R 33 , R 34 , respectively) that may be present in the phenyl ring.
  • R 3 is independently selected from F, CI, Br, CN , C1-C4- alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxy, Ci-C 4 -haloalkoxy, S(Ci-C 4 -alkyl), S(0)(Ci-C 4 -alkyl) and S(0) 2 (Ci-C 4 -alkyl).
  • R 3 is halogen, in particular Br, F or CI, more specifically F or CI.
  • R 3 is CN
  • R 3 is Ci-C6-alkyl, in particular Ci-C4-alkyl, such as CH 3 .
  • R 3 is Ci-C6-haloalkyl, in particular Ci-C4-haloalkyl, such as CF 3 , CHF 2 , CH 2 F, CCI 3 , CHCI 2 or CH 2 CI.
  • R 3 is Ci-C6-alkoxy, in particular Ci-C4-alkoxy, more specifically Ci-C2-alkoxy such as OCH3 or OCH2CH3.
  • R 3 is Ci-C6-haloalkoxy, in particular C1-C4- haloalkoxy, more specifically Ci-C 2 -haloalkoxy such as OCF 3 , OCHF 2 , OCH 2 F, OCCI 3 , OCHC or OCH2CI, in particular OCF 3 , OCHF 2 , OCCI 3 or OCHC .
  • R 3 is C2-C6-alkynyl or C2-C6-haloalkynyl, in particular C2-C 4 -alkynyl or C2-C 4 -haloalkynyl, such as C CH.
  • R 3 is selected from S(Ci-C2-alkyl), S(0)(Ci-C2-alkyl) and S(0) 2 (Ci-C 2 -alkyl), in particular SCH 3 , S(0)(CH 3 ) and S(0) 2 (CH 3 ).
  • R 3 is unsubstituted phenyl or phenyl that is substituted by one, two, three or four R 3a , as defined herein.
  • R 3 is unsubstituted phenoxy or phenoxy that is substituted by one, two, three or four R 3a , as defined herein.
  • R 3 is unsubstituted 5- or 6-membered heteroaryl.
  • R 3 is 5- or 6-membered heteroaryl that is substituted by one, two or three R 3a , as defined herein.
  • the heteroaryl in each case is 5-membered such as .
  • the heteroaryl in each case is 6-membered such as .
  • R 3 is unsubstituted 5- or 6-membered heteroaryloxy.
  • R 3 is 5- or 6-membered heteroaryloxy that is substituted by one, two or three R 3a , as defined herein.
  • the heteroaryloxy in each case is 5-membered.
  • the heteroaryloxy in each case is 6-membered.
  • R 3a is independently selected from halogen, CN, NO2, OH, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, C3-C8- cycloalkyl, Cs-Cs-halocycloalkyl, Ci-C 4 -alkoxy and Ci-C 4 -halogenalkoxy, in particular selected from halogen, CN, Ci-C2-alkyl, Ci-C2-haloalkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C1-C2- alkoxy and Ci-C2-halogenalkoxy.
  • R 3a is independently selected from F, CI, CN, OH, CH3, halomethyl, cyclopropyl, halocyclopropyl, OCH3 and halogenmethoxy.
  • R 3 Particularly preferred embodiments of R 3 according to the invention are in Table P3 below, wherein each line of lines P3-1 to P3-16 corresponds to one particular embodiment of the inven- tion, wherein P3-1 to P3-16 are also in any combination with one another a preferred embodiment of the present invention.
  • P3-1 to P3-16 are also in any combination with one another a preferred embodiment of the present invention.
  • R 4 there can be zero, one, two, three, four or five R 4 present, namely for m is 0, 1 , 2, 3, 4 or 5.
  • m is 0, 1 , 2, 3 or 4.
  • m is 0. According to a further embodiment, m is 1 , 2, 3 or 4, in particular 1 , 2 or 3, more specifically 1 or 2. According to one specific embodiment thereof, m is 1 , according to a further specific embodiment, m is 2.
  • m is 2, 3 or 4.
  • m is 3.
  • one R 4 is attached to the para-position (4- position).
  • one R 4 is attached to the meta-position (3- position).
  • one R 4 is attached to the ortho-position (2- position).
  • two R 4 are attached in 2,4-position.
  • two R 4 are attached in 2,3-position.
  • two R 4 are attached in 2,5-position.
  • two R 4 are attached in 2,6-position.
  • two R 4 are attached in 3,4-position.
  • two R 4 are attached in 3,5-position.
  • three R 4 are attached in 2,4,6-position.
  • R 4a independently selected R 4a , wherein R 4a is as defined and preferably defined herein.
  • each of R 4 is unsubstituted or further substituted by one, two, three or four independently selected R 4a , wherein R 4a is as defined and preferably defined herein.
  • R 4 is independently selected from F, CI, Br, CN, Ci-C 4 -alkyl, Ci-C 4 -haloalkyl, Ci-C 4 -alkoxy, Ci-C 4 -haloalkoxy, S(Ci-C 4 -alkyl), S(0)(Ci-C 4 -alkyl) and S(0) 2 (Ci- C 4 -alkyl).
  • R 4 is independently selected from halogen, in particular from Br, F and CI, more specifically from F and CI.
  • R 4 is CN
  • R 4 is N0 2 .
  • R 4 is OH.
  • R 4 is SH.
  • R 4 is Ci-C6-alkyl, in particular Ci-C 4 -alkyl, such as CH3.
  • Further appropriate alkyls are ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.
  • R 4 is Ci-C6-haloalkyl, in particular Ci-C 4 -haloalkyl, such as CF 3 , CHF 2 , CH 2 F, CCI 3 , CHCI 2 or CH 2 CI.
  • R 4 is Ci-C6-alkyl, preferably Ci-C 4 -alkyl, substituted by OH, more preferably CH 2 OH, CH 2 CH 2 OH, CH 2 CH 2 CH 2 OH, CH(CH 3 )CH 2 OH,
  • R 4 is CH 2 CH(CH 3 )OH, CH 2 CH 2 CH 2 CH 2 OH.
  • R 4 is CH 2 OH.
  • R 4 is Ci-C6-alkyl, preferably Ci-C 4 -alkyl substituted by CN, more preferably CH 2 CN, CH 2 CH 2 CN, CH 2 CH 2 CH 2 CN, CH(CH 3 )CH 2 CN, CH 2 CH(CH 3 )CN, CH 2 CH- 2 CH 2 CH 2 CN.
  • R 4 is CH 2 CH 2 CN.
  • R 4 is CH(CH 3 )CN.
  • R 4 is Ci-C 4 -alkoxy-Ci-C6-alkyl, more preferably Ci-C 4 -alkoxy-Ci-C 4 -alkyl.
  • R 4 is CH 2 OCH 3 .
  • R 4 is CH 2 CH 2 OCH 3 .
  • R 4 is CH(CH 3 )OCH 3 .
  • R 4 is CH(CH 3 )OCH 2 CH 3 .
  • R 4 is CH 2 CH 2 OCH 2 CH 3 .
  • R 4 is Ci-C 4 -haloalkoxy-Ci-C6- alkyl, more preferably Ci-C 4 -alkoxy-Ci-C 4 -alkyl.
  • R 4 is CH 2 OCF 3 .
  • R 4 is CH 2 CH 2 OCF 3 .
  • R 4 is
  • R 4 is CH 2 CH 2 OCCI 3 .
  • R 4 is Ci-C6-alkoxy, in particular Ci-C 4 -alkoxy, more specifically Ci-C 2 -alkoxy such as OCH 3 or OCH 2 CH 3 .
  • R 4 is Ci-C6-haloalkoxy, in particular C1-C4- haloalkoxy, more specifically Ci-C 2 -haloalkoxy such as OCF 3 , OCHF 2 , OCH 2 F, OCCI 3 , OCHCI 2 or OCH 2 CI, in particular OCF 3 , OCHF 2 , OCCI 3 or OCHCI 2 .
  • R 4 is Ci-C 4 -alkoxy-C 2 -C6-alkenyl, more preferably
  • R 4 is C 3 -C8-cycloalkyl-C 2 -C6- alkenyl, preferably C 3 -C6-cycloalkyl-C 2 -C 4 -alkenyl.
  • R 4 is C 3 -C6-halocycloalkyl-C 2 -C 4 -alkenyl, preferably C 3 -C8-halocycloalkyl-C 2 -C6-alkenyl.
  • R 4 is C 2 -C6-alkynyl or C 2 -C6-haloalkynyl, in particular C 2 -C 4 -alkynyl or C 2 -C 4 -haloalkynyl, such as C ⁇ CH, CH 2 CCH or CH 2 CCCH 3 .
  • R 4 is C 2 -C6-alkynyl, preferably C 2 -C 4 -alkynyl, substituted by OH, more preferably, CCOH, CH 2 CCOH. In a special embodiment R 4 is CCOH. In a further special embodiment R 4 is CH 2 CCOH. According to a further specific embodiment R 4 is Ci-C 4 -alkoxy-C 2 -C6-alkynyl, more preferably Ci-C 4 -alkoxy-C 2 -C 4 -alkynyl. In a special embodiment R 4 is CCOCH 3 . In a further special embodiment R 4 is CH 2 CCOCH 3 .
  • R 4 is Ci-C 4 -haloalkoxy-C 2 -C6-alkynyl, more preferably Ci-C 4 -haloalkoxy- C 2 -C 4 -alkynyl.
  • R 4 is CCOCF 3 .
  • R 4 is CH 2 CCOCF 3 .
  • R 4 is CCOCCI 3 .
  • R 4 is CH 2 CCOCCI 3 .
  • R 4 is C 3 -C8-cycloalkyl-C 2 -C6- alkynyl, preferably C 3 -C6-cycloalkyl-C 2 -C 4 -alkynyl.
  • R 4 is C 3 -C6-halocycloalkyl-C 2 -C 4 -alkynyl, preferably C 3 -C8-halocycloalkyl-C 2 -C6-alkynyl.
  • R 4 is C 3 -C8-cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, in particular cyclopropyl or cyclobutyl.
  • R 4 is cyclopropyl.
  • R 4 is cyclobutyl.
  • R 4 is cyclopentyl.
  • R 4 is cyclohexyl.
  • R 4 is C 3 -C8-cycloalkoxy, preferably C 3 -C6-cycloalkoxy. In a special embodiment R 4 is O-cyclopropyl.
  • R 4 is C 3 -C8-halocycloalkyl, more preferably fully or partially halogenated C 3 -C6-cycloalkyl.
  • R 4 is fully or partially halogenated cyclopropyl.
  • R 4 is 1 -CI-cyclopropyl.
  • R 4 is 2-CI-cyclopropyl.
  • R 4 is 1 -F-cyclopropyl.
  • R 4 is 2-F-cyclopropyl.
  • R 4 is fully or partially halo- genated cyclobutyl.
  • R 4 is 1 -CI-cyclobutyl.
  • R 4 is 1 -F-cyclobutyl. In a further special embodiment R 4 is 3,3-CI 2 -cyclobutyl. In a further special embodiment R 4 is 3,3-F 2 -cyclobutyl. According to a specific embodiment R 4 is C 3 - Cs-cycloalkyl substituted by Ci-C4-alkyl, more preferably is C3-C6-cycloalkyl substituted by Ci- C4-alkyl. In a special embodiment R 4 is 1 -CH3-cyclopropyl. According to a specific embodiment R 4 is C3-C8-cycloalkyl substituted by CN, more preferably is C3-C6-cycloalkyl substituted by CN.
  • R 4 is 1 -CN-cyclopropyl.
  • R 4 is C3-C8-cycloalkyl-C3-C8-cycloalkyl, preferably C3-C6-cycloalkyl-C3-C6-cycloalkyl.
  • R 4 is cyclopropyl-cyclopropyl.
  • R 4 is 2-cyclopropyl- cyclopropyl.
  • R 4 is Cs-Cs-cycloalkyl-Cs-Cs- halocycloalkyl, preferably C3-C6-cycloalkyl-C3-C6-halocycloalkyl.
  • R 4 is C3-C8-cycloalkyl-Ci-C4-alkyl, preferably C3-C6- cycloalkyl-Ci-C4-alkyl.
  • R 4 is CH(CH3)(cyclopropyl).
  • R 4 is CH2-(cyclopropyl).
  • R 4 is C3-C8-cycloalkyl-Ci-C4-alkyl wherein the alkyl moiety can be substituted by one, two, three or up to the maximum possible number of identical or different groups R a as defined and preferably herein and the cycloalkyi moiety can be substituted by one, two, three or up to the maximum possible number of identical or different groups R b as defined and preferably herein.
  • R 4 is C3-C8-cycloalkyl-Ci-C4-haloalkyl, C3-C6-cycloalkyl-Ci- C4-haloalkyl. According to a specific embodiment R 4 is C3-C8-halocycloalkyl-Ci-C4-alkyl, C3-C6- halocycloalkyl-Ci-C4-alkyl. In a special embodiment R 4 is fully or partially halogenated cyclopro- pyl-Ci-C4-alkyl. In a further special embodiment R 4 is 1 -CI-cyclopropyl-Ci-C4-alkyl. In a further special embodiment R 4 is 1 -F-cyclopropyl-Ci-C4-alkyl.
  • R 4 is N H2.
  • R 4 is NH(Ci-C4-alkyl). According to a specific embodiment R 4 is NH(CH3). According to a specific embodiment R 4 is NH(CH2CH3). According to a specific embodiment R 4 is NH(CH2CH2CH3). According to a specific embodiment R 4 is
  • R 4 is NI-KCI-bCI-bCI-bCHs). According to a specific embodiment R 4 is NH(C(CH 3 ) 3 ).
  • R 4 is N(Ci-C4-alkyl)2. According to a specific embodiment R 4 is N(CH3)2. According to a specific embodiment R 4 is N(CH2CH3)2. According to a specific embodiment R 4 is N(CH2CH 2 CH3)2. According to a specific embodiment R 4 is N(CH(CH 3 )2)2.
  • R 4 is N(CH2CH2CH2CH3)2. According to a specific embodiment R 4 is NH(C(CH 3 ) 3 )2.
  • R 4 is NH(C3-C8-cycloalkyl) preferably NH(C3-C6- cycloalkyl). According to a specific embodiment R 4 is NH(cyclopropyl). According to a specific embodiment R 4 is NH(cyclobutyl). According to a specific embodiment R 4 is NH(cyclopentyl). According to a specific embodiment R 4 is NH(cyclohexyl).
  • R 4 is N(C3-C8-cycloalkyl)2 preferably N(C3-C6- cycloalkyl)2. According to a specific embodiment R 4 is N(cyclopropyl)2. According to a specific embodiment R 4 is N(cyclobutyl)2. According to a specific embodiment R 4 is N(cyclopentyl)2.
  • R 4 is selected from S(Ci-C2-alkyl), S(0)(Ci-C2-alkyl) and S(0) 2 (Ci-C 2 -alkyl), in particular SCH 3 , S(0)(CH 3 ) and S(0) 2 (CH 3 ).
  • R 4 is selected from S(Ci-C 2 -haloalkyl), S(0)(Ci-C 2 -haloalkyl) and S(0) 2 (Ci-C 2 - haloalkyl), such as SO2CF3.
  • R 4 Particularly preferred embodiments of R 4 according to the invention are in Table P4 below, wherein each line of lines P4-1 to P4-16 corresponds to one particular embodiment of the inven- tion, wherein P4-1 to P4-16 are also in any combination with one another preferred embodiments of the present invention.
  • P4-1 to P4-16 are also in any combination with one another preferred embodiments of the present invention.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule I, leur utilisation comme fongicides et leur préparation, des intermédiaires de ces composés ainsi que la préparation et l'utilisation de ces intermédiaires. Les substituants sont décrits dans les revendications et la description.
PCT/EP2014/060000 2013-05-17 2014-05-15 Composés [1,2,4]triazole et imidazole substitués Ceased WO2014184309A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13168311 2013-05-17
EP13168311.2 2013-05-17

Publications (1)

Publication Number Publication Date
WO2014184309A1 true WO2014184309A1 (fr) 2014-11-20

Family

ID=48428390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/060000 Ceased WO2014184309A1 (fr) 2013-05-17 2014-05-15 Composés [1,2,4]triazole et imidazole substitués

Country Status (1)

Country Link
WO (1) WO2014184309A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815798B2 (en) 2014-03-26 2017-11-14 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
US10053432B2 (en) 2013-12-12 2018-08-21 Basf Se Substituted [1,2,4]triazole and imidazole compounds
US10112913B2 (en) 2014-05-13 2018-10-30 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
US10450279B2 (en) 2014-06-06 2019-10-22 Basf Se Substituted [1,2,4]triazole compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131845A2 (fr) * 1983-07-13 1985-01-23 Bayer Ag Utilisation de diazolylalkylecarbinols substitués pour la protection de plantes contre les champignons
CN1923819A (zh) * 2006-10-12 2007-03-07 青岛科技大学 含芳醚双三氮唑类化合物及其用途
WO2013007767A1 (fr) * 2011-07-13 2013-01-17 Basf Se Composés fongicides 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol substitués

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131845A2 (fr) * 1983-07-13 1985-01-23 Bayer Ag Utilisation de diazolylalkylecarbinols substitués pour la protection de plantes contre les champignons
CN1923819A (zh) * 2006-10-12 2007-03-07 青岛科技大学 含芳醚双三氮唑类化合物及其用途
WO2013007767A1 (fr) * 2011-07-13 2013-01-17 Basf Se Composés fongicides 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol substitués

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053432B2 (en) 2013-12-12 2018-08-21 Basf Se Substituted [1,2,4]triazole and imidazole compounds
US9815798B2 (en) 2014-03-26 2017-11-14 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
US10112913B2 (en) 2014-05-13 2018-10-30 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
US10450279B2 (en) 2014-06-06 2019-10-22 Basf Se Substituted [1,2,4]triazole compounds

Similar Documents

Publication Publication Date Title
US11064697B2 (en) Pyridine compounds useful for combating phytopathogenic fungi
CA2978037A1 (fr) Composes de quinoleine
US10696634B2 (en) Pyridine compounds as fungicides
CN102803232A (zh) 杀真菌的具有5-硫取代基的1,2,4-三唑衍生物
CN101945580A (zh) 唑基甲基环氧乙烷、其应用和包含它们的组合物
US20120077676A1 (en) Antifungal 1,2,4-Triazolyl Derivatives Having a 5-Sulfur Substituent
EP3383849A1 (fr) Composés pyridine utilisés comme fongicides
US20110172098A1 (en) Imidazole and Triazole Compounds, Their Use and Agents Containing the Same
US20110172097A1 (en) Imidazole and Triazole Compounds, Their Use and Agents Containing The Same
US20110172099A1 (en) Imidazole and Triazole Compounds, Their Use and Agents Containing the Same
WO2014095381A1 (fr) Composés imidazolyl et triazolyl fongicides
WO2014184309A1 (fr) Composés [1,2,4]triazole et imidazole substitués
US20110160056A1 (en) Triazole compounds, the use thereof and preparations containing these compounds
US20110172095A1 (en) Triazole Compounds, Use Thereof and Agents Containing Same
US20110172096A1 (en) Triazole Compounds, The Use Thereof and Preparations Containing These Compounds
WO2014198553A1 (fr) Composés imidazole et triazole [1,2,4]substitués
WO2014198557A1 (fr) Composés imidazole et triazole [1,2,4] substitués
CN102459201A (zh) 杀真菌的1，2，4-三唑衍生物
CN102177142A (zh) 三唑和咪唑化合物、其应用和含有它们的试剂
WO2018054723A1 (fr) Composés de pyridine pour lutter contre des champignons nocifs phytopathogènes
US20110177950A1 (en) Imidazole and Triazole Compounds, Their Use and Agents Containing the Same
CN102149686A (zh) 咪唑和三唑化合物、其应用和含有这些化合物的制剂
US20200187500A1 (en) Pyridine compounds
CA2990991C (fr) Composes pyridine utiles pour lutter contre des champignons phytopathogenes
US20110160055A1 (en) Imidazole and Triazole Compounds as Fungicides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14726557

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14726557

Country of ref document: EP

Kind code of ref document: A1